{"id":"NCT01423253","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Major Depressive Disorder With Mixed Features - Extension","officialTitle":"A 12-Week, Open-Label Extension Study For the Treatment of Major Depressive Disorder With Mixed Features","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2011-08-25","resultsPosted":"2015-10-14","lastUpdate":"2016-04-08"},"enrollment":48,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Lurasidone","otherNames":["Latuda"]}],"arms":[{"label":"Lurasidone 20, 40, 60 mg","type":"EXPERIMENTAL"}],"summary":"Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features over time.","primaryOutcome":{"measure":"Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"12 Weeks","effectByArm":[{"arm":"Lurasidone 20, 40, 60 mg","deltaMin":66.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":48},"commonTop":["Akathisia","Diarrhoea","Upper respiratory tract infection","Nausea","Fatigue"]}}